Nitrile compound as well as preparation method and application thereof

By designing and preparing 3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile compounds, targeting eEF2K to solve the insufficient activity of existing inhibitors Problem, effective inhibition of malignant tumor cells is achieved and toxicity to normal cells is reduced.

CN119019341AActive Publication Date: 2024-11-26SUZHOU UNIV +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202310580404.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-23
Publication Date
2024-11-26
Estimated Expiration
2043-05-23

AI Technical Summary

Technical Problem

Existing eEF2K small molecule inhibitors have weak cellular inhibitory activity or low degradation rates, making it difficult to effectively treat malignant tumors.

Method used

A 3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile compound and its preparation method are designed, and the diazotization coupling reaction and correlation are carried out. The compound was prepared by ring reaction and used to target eEF2K to inhibit its activity.

Benefits of technology

This compound showed excellent selectivity and inhibitory effects, had a significant inhibitory effect on malignant tumor cells, especially triple-negative breast cancer cells, and was less toxic to normal cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019341A_ABST
    Figure CN119019341A_ABST
Patent Text Reader

Abstract

The invention relates to a nitrile compound as well as a preparation method and application thereof. The general formula of the compound disclosed by the invention is # imgabs0 #, wherein # imgabs1 # is independently selected from substituted or unsubstituted aryl or heteroaryl. The nitrile compound is applied to an eEF2K inhibitor and / or a degradation agent, and is further applied to preparation of medicines for treating tumors or neuropsychiatric diseases. According to the present invention, the nitrile compound provides strong malignant tumor cell resistance activity through targeting the eEF2K protein, provides small influence on normal cell activity, provides strong anti-tumor potential, and has high safety, such that the nitrile compound has good application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to a nitrile compound or an isomer thereof, a preparation method thereof and use thereof in preventing and / or treating malignant tumors associated with eEF2K. Background Art

[0002] Commonly used anti-tumor drugs include biological alkylating compounds, antimetabolites, antibiotics, natural products and their derivatives, and protein tyrosine kinase inhibitors. However, these anti-malignant tumor drugs have many disadvantages, such as: biological alkylating compounds will inhibit other rapidly proliferating cells when inhibiting tumor cells, and this type of compound is also very easy to develop drug resistance; antimetabolites have a narrow anti-tumor spectrum; antibiotic compounds have high bone marrow suppression toxicity; natural products are limited in source and difficult to fully synthesize. Therefore, it is urgent to develop anti-tumor drugs with low toxicity, high activity and simple source.

[0003] Eukaryotic elongation factor 2 kinase (eEF2K), as a member of the α-kinase family of atypical kinases, is a calcium / calmodulin-dependent kinase with unique structure and function. It participates in the calmodulin-mediated signaling pathway in the human body, catalyzing the phosphorylation of the Thr56 site of eukaryotic elongation factor 2 (eEF2) and causing its inactivation, thereby inhibiting the protein peptide chain elongation process of mRNA translation.

[0004] eEF2K is highly expressed in a variety of malignant tumor cells, such as lung cancer, colon cancer, breast cancer and esophageal cancer. When normal tissues encounter nutrient deficiency, mTORC and Erk are inhibited, and the AMP / ATP ratio increases, thereby activating eEF2K to phosphorylate eEF2 and inhibit protein synthesis, promote cell autophagy, reduce the tumor cells' need for peripheral environmental nutrition, and ultimately increase the survival rate of tumor cells; conversely, when eEF2K is inhibited, the growth of tumor cells will be inhibited (Lung Cancer, 2018, 124, 31-39; Oncotarget, 2017, 8, 11641-11658; Radiother Oncol. 2017, 124, 439-447; Apoptosis. 2014, 19, 241-258; Cell, 2013, 153, 1064-1079).

[0005] In summary, eEF2K is a very potential target for the treatment of malignant tumors, and small molecule compounds targeting eEF2K protein will be expected to alleviate or treat malignant tumors (such as triple-negative breast cancer).

[0006] At present, a variety of small molecule compounds targeting eEF2K have been discovered, including inhibitors and protein degradation targeting complexes (PROTACs) (Int. J. Mol. Sci. 2021, 22, 2408), such as the selective eEF2K inhibitor A-484954 developed by Abbott, which inhibits eEF2K by competing for ATP binding to eEF2K (IC 50 =0.28 μM), but the cell activity was weak (IC 50 >20 μM) (J. Biol. Chem. 2011, 286, 43951-44398; Bioorg. Med. Chem. 2014, 22, 4910-4916). In addition, PROTAC derivatives of A-484954 were found, and their maximum eEF2K degradation rate (Dr) value was only 56.7%, so these compounds are currently only used as pharmacological tools. Summary of the invention

[0007] Therefore, the technical problem to be solved by the present invention is to overcome the shortcomings of existing eEF2K small molecule inhibitors in the prior art, such as weak cell inhibitory activity or low degradation rate.

[0008] In order to solve the above technical problems, the present invention provides a nitrile compound and a pharmaceutically acceptable salt or hydrate thereof and its application in anti-malignant tumor related to eEF2K.

[0009] The first object of the present invention is to provide a 3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile compound, the general formula of which is shown in Formula A:

[0010] in, are independently selected from substituted or unsubstituted aryl or heteroaryl.

[0011] In one embodiment of the present invention, the aryl or heteroaryl group is a substituted or unsubstituted benzene ring, a naphthalene ring, a biphenyl ring, or an aromatic heterocycle composed of one or more N, O, and S; further, it includes a pyrrole ring, a pyrazole ring, a thiazole ring, an oxazole ring, a pyridine ring, etc.; the substituent group in the substituted or unsubstituted aryl or heteroaryl group is selected from one or more of hydrogen, alkyl, aralkyl, heteroaryl, alkoxy, halogen, cyano, acyloxy, carbamoyl, acyl and sulfonyl.

[0012] Furthermore, the It is phenyl, 3-methylphenyl, 4-methylphenyl or 3,4-dimethylphenyl, and more preferably 3,4-dimethylphenyl.

[0013] Furthermore, the Preferred are 3-fluorophenyl, 3-trifluoromethylphenyl and 3-methylphenylphenyl.

[0014] In one embodiment of the present invention, the 3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile compound is 1-(4-benzyl-2-(3,4-dimethylphenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-cyanide, 2-(3,4-dimethylphenyl)-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 2-(3,4-dimethylphenyl)-4-(3-fluorobenzyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 2-(3,4-dimethylphenyl)-4-(4-methylbenzyl)-3,5-dioxo-2,3, 4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 2-(3,4-dimethylphenyl)-4-(2-methylbenzyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 2-(3,4-dimethylphenyl)-3,5-dioxo-4-(3-trifluoromethyl)benzyl)-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 2-(3,4-dimethylphenyl)-3,5-dioxo-4-propyl-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 4-ethyl-3,5-dioxo-2-phenyl-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 4-methyl-3,5-dioxo-2- Phenyl-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 4-benzyl-3,5-dioxo-2-pyridine-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 4-benzyl-2-naphthyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 2-(3,4-dimethylphenyl)-3,5-dioxo-4-(pyridin-2-ylmethyl)-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 2-(1,1'-biphenyl)-4-yl)-4-benzyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 4-benzyl-2-(4-methylsulfonyl)phenyl-3, 5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 4-benzyl-2-(4-fluorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 2-(3,4-dimethylphenyl)-4-naphth-2-ylmethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 2-(3,4-dimethylphenyl)-4-(3-methylsulfonyl)benzyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 4-benzyl-3,5-dioxo-2-p-tolyl-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 4-benzyl-3,5-dioxo-2-p-tolyl-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile,5-dioxo-2-m-tolyl-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile or 4-benzyl-2-(4-methoxyphenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile.

[0015] In one embodiment of the present invention, the is phenyl, 3-methylphenyl, 4-methylphenyl or 3,4-dimethylphenyl.

[0016] In one embodiment of the present invention, the pharmaceutically acceptable salt is selected from at least one of inorganic acid salts, organic acid salts, alkyl sulfonates and aryl sulfonates.

[0017] The second object of the present invention is to provide a method for preparing 3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile compounds, comprising the following steps:

[0018] (1) reacting the compound represented by formula A1 with the compound represented by formula A2 by diazotization coupling reaction to obtain the compound represented by formula A3;

[0019] (2) The compound represented by formula A3 is cyclized under acidic conditions to obtain the compound represented by formula A4, and the compound represented by formula A4 is reacted with a halogenated hydrocarbon under alkaline conditions. Substitution reaction occurs to obtain the compound represented by formula A, i.e., the nitrile compound, wherein the structural formula of the compound represented by formula A1-A4 and formula A is as follows:

[0020]

[0021] is independently selected from substituted or unsubstituted aryl or heteroaryl. Further, preferably, it is phenyl, 3,4-dimethylphenyl, pyridyl, biphenyl or naphthalene ring.

[0022] Furthermore, the halogenated hydrocarbon The halogen X can be F, Cl, Br, I, preferably Br.

[0023] Furthermore, in step (1), the molar ratio of the compound represented by formula A1 to the compound represented by formula A2 is 1:1-1:2.

[0024] Furthermore, in step (2), the pH value of the acidic condition is 1-4; and the pH value of the alkaline condition is 8-10.

[0025] Further, the preparation method of the 3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-nitrile compound is:

[0026] Step 1: Dissolve the amine compound A1 containing a substituent in a mixture of concentrated hydrochloric acid and water, and add a diazotizing agent solution under an ice bath; after 0.5 to 1 hour, add an aqueous solution of N-cyanourea A2 and sodium acetate to the reaction solution, and after the reaction is complete, obtain compound A3.

[0027] Step 2: Compound A3 and a base are dissolved in an acid and refluxed at high temperature to undergo a ring-closing reaction, and compound A4 is obtained after the reaction is complete.

[0028] Step 3: Dissolve compound A4 in an organic solvent and carry out a substitution reaction under alkaline conditions to obtain compound A5. See the reaction flow chart Figure 2 shown.

[0029] In one embodiment of the present invention, in step 1, the diazotization reagent in the diazotization reagent solution is selected from one or more of sodium nitrite, tert-butyl nitrite, isopentyl nitrite, nitrosylsulfuric acid and nitrosate tetrafluoroborate.

[0030] Furthermore, the reagent of the diazotization reagent solution is one or more of water, sulfuric acid, hydrochloric acid, hydrobromic acid, glacial acetic acid, acetone, tetrahydrofuran, and toluene.

[0031] In one embodiment of the present invention, in step 1, the reaction conditions are: reaction temperature -5°C to 10°C, and reaction time is 2h to 6h.

[0032] In one embodiment of the present invention, in step 2, the conditions of the ring-closure reaction are: reaction temperature 100° C. to 110° C., and reaction time 3 h to 10 h.

[0033] In one embodiment of the present invention, in step 2, the base is selected from one or more of sodium acetate, potassium carbonate, potassium acetate, sodium carbonate, triethylamine and DIPEA.

[0034] In one embodiment of the present invention, in step 2, the acid is selected from one or more of glacial acetic acid, formic acid, methanesulfonic acid and trifluoroacetic acid.

[0035] In one embodiment of the present invention, in step 3, the reaction temperature is 10°C to 40°C, and the reaction time is 10h to 16h.

[0036] In one embodiment of the present invention, in step 3, the organic solvent is selected from one or more of acetonitrile, acetone, DMF, tetrahydrofuran, ethanol and DMSO.

[0037] In one embodiment of the present invention, in step 3, the pH value of the alkaline condition is 7-11.

[0038] The third object of the present invention is to provide the use of the 3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile compounds and their isomers or pharmaceutically acceptable salts or hydrates in the preparation of eEF2K inhibitors and / or degraders.

[0039] The fourth object of the present invention is to provide the use of the 3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile compounds and their isomers or pharmaceutically acceptable salts or hydrates in the preparation of tumor or neuropsychiatric disease drugs.

[0040] In one embodiment of the present invention, the tumor is triple-negative breast cancer, lung cancer, colon cancer, or breast cancer and esophageal cancer.

[0041] In one embodiment of the present invention, the neuropsychiatric disease is epilepsy, depression, Parkinson's disease, Alzheimer's disease and related dementia diseases.

[0042] The above technical solution of the present invention has the following advantages compared with the prior art:

[0043] The present invention designs nitrile compounds having a general structure of formula A and finds that compounds having such a structure exhibit excellent selectivity and inhibitory effects on eEF2K. The present invention discloses and illustrates the relationship between the structure and activity of nitrile compounds in a wider range and in a more in-depth and comprehensive manner, and has important application value. The nitrile compounds of the present invention can be used to treat malignant tumors (e.g., triple-negative breast cancer) when acting on eEF2K. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] In order to make the content of the present invention more clearly understood, the present invention is further described in detail below according to specific embodiments of the present invention in conjunction with the accompanying drawings, wherein

[0045] Figure 1 SPR binding experiment diagram of representative compound Z1 and eEF2K protein.

[0046] Figure 2 Flow chart of the synthesis reactions in Examples 1, 11, 12, 14, 15, 16, 17, 18, 22, 23 and 24 of the present invention.

[0047] Figure 3 The synthetic reaction flow chart of the final product of the present invention. DETAILED DESCRIPTION

[0048] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.

[0049] In the following examples of the present invention, the structures of the compounds are determined by nuclear magnetic resonance (NMR) or mass spectrometry (MS). NMR is measured by Agilent 300MHz or 600MHz instrument, the measuring solvent is deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), the internal standard is tetramethylsilane (TMS), and MS is measured by GCT PremierTM (CI) mass spectrometer, and the CI source (70ev) is used unless otherwise specified.

[0050] Thin layer chromatography silica gel plate uses Yantai Huanghai HSGZ174 or Qingdao GZ174 silica gel plate. The specification of silica gel plate used in thin layer chromatography (TLC) is 0.15mm-0.2mm. Column chromatography generally uses Yantai Huanghai 100-200 mesh or 200-300 mesh silica gel as carrier.

[0051] The reaction conditions of nitrogen filling refer to that the reaction bottle is connected to a nitrogen balloon with a volume of about 1 L. The reaction conditions are room temperature (rt), and the temperature range is 20°C-30°C.

[0052] In the following examples of the present invention, all solvents were redistilled before use, and the anhydrous solvents used were obtained by drying according to standard methods.

[0053] Embodiment 1:

[0054] This example provides the synthesis of compound Z1, as follows:

[0055] (1) The synthetic route of compound Z1 is as follows Figure 2 shown.

[0056] Wherein, the reaction conditions are: step a: NaNO2, HCl, AcONa, pyridine, 0°C; step b: AcONa, AcOH, 110°C; step c: K2CO3, acetonitrile.

[0057] (2) Specific synthesis steps:

[0058] Step a: Synthesis of Compound Z1-C

[0059] 5g (41.26mmol) of 3,4-dimethylaniline (Z1-A) was placed in a 250mL round-bottom flask, and 60mL of water and 22.5mL of concentrated hydrochloric acid were added. The solution was placed in an ice bath and stirred to cool down, and then 3.94g (57.76mmol) of sodium nitrite was dissolved in 20mL of water and slowly added to the previous solution, and TLC was detected. After the reaction of 3,4-dimethylaniline was completed, 50mL of N-cyanoacetyl urethane (Z1-B) 6.7g (41.26mmol) and sodium acetate 10g (123.78mmol) were added to the reaction solution in a mixture of pyridine: water (volume ratio of 1:1), and after the reaction was completed, it was filtered, washed with water 3 times, and dried to obtain 10.04g of yellow solid with a yield of 84.44%. 1 H NMR (300MHz, DMSO-d6) δ11.95 (s, 1H), 10.42 (d, J = 4.5Hz, 1H), 7.50-7.35 (m, 2H), 7.11 ( d,J=7.9Hz,1H),4.15(tt,J=7.7,4.7Hz,2H),2.18(d,J=11.3Hz,6H),1.41-1.16(m,3H).

[0060] Step b: Synthesis of compound Z1-D

[0061] Z1-C 10.04g (34.82mmol) and sodium acetate 14.28g (174.12mmol) were placed in a 250mL round-bottom flask, dissolved with 120mL glacial acetic acid, and refluxed at 110°C. After the reaction was completed, a large amount of water was added until no solid was precipitated, filtered, washed with water three times, and dried to obtain 7.8g of light yellow solid with a yield of 92.46%. 1 H NMR (300MHz, CDCl3) δ9.31 (s, 1H), 7.32 (dd, J = 10.7, 5.0Hz, 3H), 2.40 (s, 6H).

[0062] Step c: Synthesis of compound Z1

[0063] 1.68 g (6.94 mmol) of Z1-D and 1.92 g (13.87 mmol) of potassium carbonate were placed in a 250 mL round-bottom flask, 70 mL of acetonitrile was added and stirred in an ice bath, and benzyl bromide was slowly added dropwise. After the reaction was completed, extraction was performed, washing was performed with a saturated NaCl solution, drying was performed with anhydrous sodium sulfate, evaporation was performed under reduced pressure, and the concentrate was purified by chromatography column (PE: EA = 10: 1 (v / v)) to obtain 1.99 g of a white solid with a yield of 86.33%. 1H NMR (300MHz, CDCl3) δ7.62-7.49(m,2H),7.34(q,J=2.8Hz,3H),7.26-7.13(m,3H),5.16(s,2H),2.31(s,6H).

[0064] Embodiment 2:

[0065] This example provides the synthesis of compound Z2, as follows:

[0066] (1) The synthetic route of compound Z2 is as follows:

[0067]

[0068] The reaction conditions are (a) K2CO3, iodomethane, acetonitrile, rt; (b) HCl, glacial acetic acid, 110°C; (c) oxalyl chloride, DCM, DMF, N2, rt; (d) ethyl 3-piperidinylcarboxylate, Et3N, DCM, 0°C

[0069] (2) Specific synthesis steps of compound Z2:

[0070] Compound Z1-D 400 mg (1.65 mmol) and potassium carbonate 456.43 mg (3.30 mmol) were placed in a 100 mL round-bottom flask, 20 mL of acetonitrile was added and stirred in an ice bath, and iodomethane was slowly added dropwise. After the reaction was completed, extraction was performed, and the mixture was washed with a saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography (PE: EA = 10: 1 (v / v)) to obtain 220 mg of a white solid with a yield of 51.99%.

[0071] Embodiment 3:

[0072] This example provides the synthesis of compound Z3, as follows:

[0073] (1) The synthetic route of compound Z3 is as follows:

[0074]

[0075] Wherein, the reaction conditions are: step a: K2CO3, acetonitrile, 3-fluorobenzyl bromide.

[0076] (2) Synthesis of compound Z3

[0077] Compound Z1-D 1.68g (6.94mmol) and potassium carbonate 1.92g (13.87mmol) were placed in a 250mL round-bottom flask, 70mL acetonitrile was added and stirred in an ice bath, and 3-fluorobenzyl bromide was slowly added dropwise. After the reaction was completed, extraction was performed, and the mixture was washed with a saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography (PE:EA=10:1 (v / v)) to obtain 1.90g of a white solid with a yield of 78.20%. 1 H NMR (500MHz, CDCl3) δ7.59(dd,J=7.9,2.2Hz,1H),7.41(d,J=2.1Hz,1H),7.34(td,J=8.0,5.0Hz,1H),7.17(dq,J=8.0,1.1Hz,1H),7 .12(dddt,J=8.0,4.2,2.2,0.9Hz,2H),7.03(tdd,J=7.9,2.0,1.3Hz,1H),5.07(t,J=1.0Hz,2H),2.28(d,J=1.1Hz,3H),2.23(s,3H).

[0078] Embodiment 4:

[0079] This example provides the synthesis of compound Z4, as follows:

[0080] (1) The synthetic route of compound Z4 is as follows:

[0081]

[0082] Among them, the reaction conditions (a) ethanol, DMSO, H2O2, NaOH

[0083] (2) Synthesis of Compound Z4

[0084] Compound Z1100 mg (300.88 mmol) was dissolved in 2 mL of ethanol and stirred at 0°C. 6 mg of NaOH, 17.47 mg of DMSO, and two drops of hydrogen peroxide solution were added and reacted overnight. After the reaction was completed, ethanol was evaporated under reduced pressure, dissolved in DCM, washed with water 2 to 3 times, washed once with saturated NaCl solution, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The solid was purified by chromatography to obtain 50 mg of a white solid with a yield of 47.43%. 1 H NMR (300MHz, CDCl3) δ8.43 (s, 1H), 7.50-7.44 (m, 2H), 7.30-7.25 (m, 3H), 7.19 (d, J = 2.1Hz, 3H), 5.92 (s, 1H), 5.15 (s, 2H), 2.22 (d, J = 3.2Hz, 6H).

[0085] Embodiment 5:

[0086] This example provides the synthesis of compound Z5, as follows:

[0087] (1) The synthetic route of compound Z5 is as follows:

[0088]

[0089] Wherein, the reaction conditions are (a) K2CO3, acetonitrile, 4-methylbenzyl bromide.

[0090] (2) Synthesis of compound Z5

[0091] Compound Z1-D 500 mg (2.06 mmol) and potassium carbonate 458.39 mg (2.48 mmol) were placed in a 100 mL round-bottom flask, 30 mL of acetonitrile was added and stirred in an ice bath, and 4-methylbenzyl bromide was slowly added dropwise. After the reaction was completed, extraction was performed, and the mixture was washed with a saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography (PE:EA=10:1 (v / v)) to obtain 538 mg of a white solid with a yield of 75.25%.

[0092] Embodiment 6:

[0093] This example provides the synthesis of compound Z6, as follows:

[0094] (1) The synthetic route of compound Z6 is as follows:

[0095]

[0096] Among them, reaction conditions (a) K2CO3, acetonitrile, 2-methylbenzyl bromide

[0097] Synthesis of compound Z6

[0098] (2) Synthesis of Compound Z6

[0099] Compound Z1-D 500 mg (2.06 mmol) and potassium carbonate 458.39 mg (2.48 mmol) were placed in a 100 mL round-bottom flask, 30 mL of acetonitrile was added and stirred in an ice bath, and 4-methylbenzyl bromide was slowly added dropwise. After the reaction was completed, extraction was performed, and the mixture was washed with a saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography (PE:EA=10:1 (v / v)) to obtain 538 mg of a white solid with a yield of 75.25%.

[0100] Embodiment 7:

[0101] This example provides the synthesis of compound Z7, as follows:

[0102] (1) The synthetic route of compound Z7 is as follows:

[0103]

[0104] Among them, reaction conditions (a) K2CO3, acetonitrile, 3-trifluoromethylbenzyl bromide

[0105] (2) Synthesis of compound Z7

[0106] 600 mg (2.48 mmol) of Z1D, 651.27 mg (2.72 mmol) of m-trifluoromethylbenzyl bromide and 684.64 mg of potassium carbonate were placed in acetonitrile and stirred for 4 h, extracted with DCM / H2O and recrystallized to obtain 670 mg of a white solid with a yield of 67.56%. 1 H NMR (400MHz, CDCl3) δ7.79(d,J=2.3Hz,1H),7.74(d,J=7.7Hz,1H),7.61(d,J=7.8Hz, 1H),7.48(t,J=7.8Hz,1H),7.24(s,1H),7.22-7.15(m,2H),5.21(s,2H),2.31(s,6H).

[0107] Embodiment 8:

[0108] This example provides the synthesis of compound Z8, as follows:

[0109] (1) The synthetic route of compound Z8 is as follows:

[0110]

[0111] (2) The synthesis of compound Z8 is the same as that of compound Z1, except that benzyl bromide is replaced by iodopropane. 1 H NMR (300MHz, CDCl3) δ7.32-7.10(m,4H),3.98(t,J=7.6Hz,2H),2.32(s,6H),1.74(q,J=7.9Hz,2H),0.99(dd,J=8.5,6.3Hz,3H).

[0112] Embodiment 9:

[0113] This example provides the synthesis of compound Z9

[0114]

[0115] The synthesis of compound Z9 is the same as that of compound Z1, except that 3,4-dimethylaniline is replaced by aniline and benzyl bromide is replaced by ethyl iodide. 1H NMR (300MHz, CDCl3) δ7.59 (s, 5H), 4.19 (q, J = 7.2Hz, 2H), 1.42 (t, J = 7.1Hz, 3H).

[0116] Embodiment 10:

[0117] This example provides the synthesis of compound Z10

[0118]

[0119] The synthesis of compound Z10 is the same as that of compound Z1, except that 3,4-dimethylaniline is replaced by aniline and benzyl bromide is replaced by methyl iodide. 1 H NMR (300MHz, CDCl3) δ7.59 (s, 5H), 4.19 (q, J = 7.2Hz, 3H).

[0120] Embodiment 11:

[0121] This example provides the synthesis of compound Z11

[0122] (1) The synthetic route of compound Z11 is as follows Figure 2 shown.

[0123] Wherein, the reaction conditions are: (a) NaNO2, HCl, AcONa, pyridine, 0°C; (b) AcONa, AcOH, 110°C; (c) K2CO3, acetonitrile;

[0124] (2) Synthesis steps of compound Z11

[0125] a) Synthesis of compound Z11-B

[0126] The synthesis of compound Z11-B is the same as compound Z1-C, except that compound Z1-A is replaced by compound Z11-A. 1 H NMR (500MHz, CDCl3) δ9.24(s,1H),8.28(dd,J=4.3,1.6Hz,1H),7.67(td,J=7.0,1.7Hz,1H),7.30(dd ,J=7.0,1.5Hz,1H),6.93(ddd,J=7.0,4.2,1.5Hz,1H),4.21(q,J=6.4Hz,2H),1.27(t,J=6.2Hz,3H).

[0127] b) Synthesis of compound Z11-C

[0128] The synthesis of compound Z11-C is the same as compound Z1-D, except that compound Z1-C is replaced by compound Z11-B.

[0129] c) Synthesis of Compound Z11

[0130] The synthesis of compound Z11 is the same as compound Z1, except that compound Z1-D is replaced by compound Z11-C. 1 H NMR (500MHz, CDCl3) δ8.41 (dd, J = 4.5, 1.7Hz, 1H), 7.72 (dd, J = 6.5, 1.5Hz, 1H), 7.64-7.58 (m, 1H), 7.33-7.21 (m, 6H), 5.08 (d, J = 1.0Hz, 2H).

[0131] Embodiment 12:

[0132] This example provides the synthesis of compound Z12

[0133] (1) The synthetic route of compound Z12 is as follows Figure 2 shown.

[0134] Wherein, the reaction conditions are: (a) NaNO2, HCl, AcONa, pyridine, 0°C; (b) AcONa, AcOH, 110°C; (c) K2CO3, acetonitrile.

[0135] (2) Synthesis steps of compound Z12

[0136] a) Synthesis of compound Z12-B

[0137] The synthesis of compound Z12-B is the same as compound Z1-C, except that compound Z1-A is replaced by compound Z12-A. 1 H NMR(500MHz, CDCl3)δ9.23(s,1H),7.92(d,J=7.6Hz,1H),7.85-7.80(m,2H),7.74(dt,J=7.4,1.9Hz ,1H),7.50-7.44(m,2H),7.37(dd,J=7.7,2.2Hz,1H),4.21(q,J=6.3Hz,2H),1.27(t,J=6.2Hz,3H).

[0138] b) Synthesis of compound Z12-C

[0139] The synthesis of compound Z12-C is the same as compound Z1-D, except that compound Z1-C is replaced by compound Z12-B.

[0140] c) Synthesis of compound Z12

[0141] The synthesis of compound Z12-D is the same as compound Z1, except that compound Z1-D is replaced by compound Z12-C. 1H NMR (500MHz, CDCl3) δ8.12 (t, J = 2.0 Hz, 1H), 7.99 (d, J = 7.2 Hz, 1H), 7.93-7.80 (m, 2H), 7.72 (dd, J = 7.2, 2.3 Hz, 1H), 7.55-7.41 (m, 2H), 7.36-7.23 (m, 5H), 5.08 (d, J = 1.1 Hz, 2H).

[0142] Embodiment 13:

[0143] This example provides the synthesis of compound Z13

[0144] (1) Synthesis route of compound Z13

[0145]

[0146] Among them, reaction conditions (a) K2CO3, acetonitrile, 2-bromomethylpyridine

[0147] (2) Synthesis of compound Z13

[0148] Compound Z1-D 500 mg (2.06 mmol) and potassium carbonate 458.39 mg (2.48 mmol) were placed in a 100 mL round-bottom flask, 30 mL of acetonitrile was added and stirred in an ice bath, and 2-bromomethylpyridine was slowly added dropwise. After the reaction was completed, extraction was performed, and the mixture was washed with a saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE:EA=10:1). 1 H NMR (500MHz, CDCl3) δ8.49(dd,J=4.1,1.7Hz,1H),7.74(td,J=7.6,1.7Hz,1H),7.59(dd,J=7.9,2.2Hz,1H),7.52(ddd,J=7.5,4.2 ,1.5Hz,1H),7.41(d,J=2.2Hz,1H),7.35(dd,J=7.8,1.3Hz,1H),7.17(dq,J=8.0,1.1Hz,1H),4.92(s,2H),2.28(d,J=1.1Hz,3H).

[0149] Embodiment 14:

[0150] This example provides the synthesis of compound Z14

[0151] (1) The synthetic route of compound Z14 is as follows Figure 2 shown.

[0152] Wherein, the reaction conditions are: (a) NaNO2, HCl, AcONa, pyridine, 0°C; (b) AcONa, AcOH, 110°C; (c) K2CO3, acetonitrile.

[0153] (1) Synthesis of compound Z14

[0154] a) Synthesis of compound Z14-B

[0155] The synthesis of compound Z14-B is the same as compound Z1-C, except that compound Z1-A is replaced by compound Z14-A.

[0156] b) Synthesis of compound Z14-C

[0157] The synthesis of compound Z14-C is the same as compound Z1-D, except that compound Z1-C is replaced by compound Z14-B.

[0158] c) Synthesis of compound Z14

[0159] The synthesis of compound Z14 is the same as compound Z1, except that compound Z1-D is replaced by compound Z14-C. 1 H NMR (500MHz, CDCl3) δ7.76-7.70(m,2H),7.70-7.65(m,2H),7.59(dd,J=8.1,1.5Hz,2H),7.48-7.35(m,3H),7.34-7.23(m,5H),5.08(d,J=1.0Hz,2H).

[0160] Embodiment 15:

[0161] This example provides the synthesis of compound Z15

[0162] (1) The synthetic route of compound Z15 is as follows Figure 2 .

[0163] Wherein, the reaction conditions are: (a) NaNO2, HCl, AcONa, pyridine, 0°C; (b) AcONa, AcOH, 110°C; (c) K2CO3, acetonitrile.

[0164] (2) Synthesis of compound Z15

[0165] a) Synthesis of compound Z15-B

[0166] The synthesis of compound Z15-B is the same as compound Z15-B, except that compound Z15-A is replaced by compound Z15-A.

[0167] b) Synthesis of compound Z15-C

[0168] The synthesis of compound Z15-C is the same as compound Z15-C, except that compound Z15-B is replaced by compound Z15-B.

[0169] c) Synthesis of compound Z15

[0170] The synthesis of compound Z15 is the same as compound Z1, except that compound Z1-D is replaced by compound Z15-C. 1 H NMR (500MHz, CDCl3) δ7.72-7.67(m,2H),7.67-7.62(m,2H),7.34-7.23(m,5H),5.08(d,J=1.0Hz,2H),3.18(s,3H).

[0171] Embodiment 16:

[0172] This example provides the synthesis of compound Z16

[0173] (1) The synthetic route of compound Z16 is as follows Figure 2 shown.

[0174] Wherein, the reaction conditions are: (a) NaNO2, HCl, AcONa, pyridine, 0°C; (b) AcONa, AcOH, 110°C; (c) K2CO3, acetonitrile;

[0175] (2) Synthesis of compound Z16

[0176] a) Synthesis of compound Z16-B

[0177] The synthesis of compound Z16-B is the same as compound Z1-C, except that compound Z1-A is replaced by compound Z16-A.

[0178] b) Synthesis of compound Z16-C

[0179] The synthesis of compound Z16-C is the same as compound Z1-D, except that compound Z1-C is replaced by compound Z16-B.

[0180] c) Synthesis of compound Z16

[0181] The synthesis of compound Z16 is the same as compound Z1, except that compound Z1-D is replaced by compound Z16-C. 1 H NMR (500MHz, CDCl3) δ7.69-7.63(m,2H),7.34-7.23(m,6H),7.16-7.10(m,2H),5.08(d,J=1.1Hz,2H).

[0182] Embodiment 17:

[0183] This example provides the synthesis of compound Z17

[0184] (1) The synthetic route of compound Z17 is as follows Figure 2 shown.

[0185] Wherein, the reaction conditions are: (a) NaNO2, HCl, AcONa, pyridine, 0°C; (b) AcONa, AcOH, 110°C; (c) K2CO3, acetonitrile.

[0186] (2) Synthesis of compound Z17

[0187] a) Synthesis of compound Z17-B

[0188] The synthesis of compound Z17-B is the same as compound Z1-C, except that compound Z1-A is replaced by compound Z17-A.

[0189] b) Synthesis of compound Z17-C

[0190] The synthesis of compound Z17-C is the same as compound Z1-D, except that compound Z1-C is replaced by compound Z17-B.

[0191] c) Synthesis of compound Z17

[0192] The synthesis of compound Z17 is the same as compound Z1, except that compound Z1-D is replaced by compound Z17-C. 1 H NMR (500MHz, CDCl3) δ9.30 (s, 1H), 7.68-7.62 (m, 2H), 7.57-7.52 (m, 2H), 7.34-7.23 (m, 6H), 5.08 (d, J = 1.0Hz, 2H), 2.16 (s, 3H).

[0193] Embodiment 18:

[0194] This example provides the synthesis of compound Z18

[0195] (1) The synthetic route of compound Z18 is as follows Figure 2 shown.

[0196] Wherein, the reaction conditions are: (a) NaNO2, HCl, AcONa, pyridine, 0°C; (b) AcONa, AcOH, 110°C; (c) K2CO3, acetonitrile.

[0197] (2) Synthesis of compound Z18

[0198] a) Synthesis of compound Z18-B

[0199] The synthesis of compound Z18-B is the same as compound Z1-C, except that compound Z1-A is replaced by compound Z18-A.

[0200] b) Synthesis of compound Z18-C

[0201] The synthesis of compound Z18-C is the same as compound Z1-D, except that compound Z1-D is replaced by compound Z18-B.

[0202] c) Synthesis of compound Z18

[0203] The synthesis of compound Z18 is the same as compound Z1, except that compound Z1-D is replaced by compound Z18-C. 1 H NMR (500MHz, CDCl3) δ7.68-7.62(m,2H),7.34-7.26(m,4H),7.30-7.22(m,2H),7.25-7.20(m,2H),5.08(d,J=1.0Hz,2H),2.28(s,3H).

[0204] Embodiment 19:

[0205] This example provides the synthesis of compound Z19

[0206] (1) Synthesis route of compound Z19

[0207]

[0208] Among them, reaction conditions (a) K2CO3, acetonitrile, β-bromomethylnaphthalene

[0209] (2) Synthesis of compound Z19

[0210] Compound Z1-D 500mg (2.06mmol) and potassium carbonate 458.39mg (2.48mmol) were placed in a 100mL round-bottom flask, 30mL acetonitrile was added and stirred in an ice bath, β-bromomethylnaphthalene. After the reaction was completed, extraction was performed, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE:EA=10:1). 1H NMR (500MHz, CDCl3) δ8.13-8.07(m,1H),7.86-7.78(m,2H),7.77-7.71(m,1H),7.59(dd,J=7.9,2.2Hz,1H),7.55-7.43(m,2 H),7.41(d,J=2.1Hz,1H),7.27-7.22(m,1H),7.17(dq,J=8.0,1.1Hz,1H),5.14(s,2H),2.28(d,J=1.1Hz,3H),2.23(s,3H).

[0211] Embodiment 20:

[0212] This example provides the synthesis of compound Z20

[0213] (1) Synthesis route of compound Z20

[0214]

[0215] Among them, reaction conditions (a) K2CO3, acetonitrile, 1-bromomethyl-3-methylsulfonylbenzene

[0216] (2) Synthesis of compound Z20

[0217] Compound Z1-D 500mg (2.06mmol) and potassium carbonate 458.39mg (2.48mmol) were placed in a 100mL round-bottom flask, 30mL acetonitrile was added and stirred in an ice bath, 1-bromomethyl-3-methylsulfonylbenzene. After the reaction was completed, extraction was performed, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE:EA=10:1). 1 H NMR (500MHz, CDCl3) δ7.78-7.72(m,2H),7.59(dd,J=7.9,2.2Hz,1H),7.46-7.37(m,3H),7.17( dq,J=8.0,1.1Hz,1H),5.06(t,J=0.9Hz,2H),3.18(s,3H),2.28(d,J=1.1Hz,3H),2.23(s,3H).

[0218] Embodiment 21:

[0219] This example provides the synthesis of compound Z21

[0220] (1) Synthesis route of compound Z21

[0221]

[0222] Among them, reaction conditions (a) K2CO3, acetonitrile, ethyl 3-(bromomethyl)benzoate (2) Synthesis of compound Z21

[0223] Compound Z1-D 500 mg (2.06 mmol) and potassium carbonate 458.39 mg (2.48 mmol) were placed in a 100 mL round-bottom flask, and 30 mL of acetonitrile was added and stirred in an ice bath, ethyl 3-(bromomethyl)benzoate. After the reaction was completed, extraction was performed, washed with saturated NaCl solution, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the concentrate was purified by chromatography column (PE:EA=10:1). 1 H NMR (500MHz, CDCl3) δ7.87 (dt, J=7.8, 1.7Hz, 1H), 7.83 (dp, J=2.0, 0.9Hz, 1H), 7.59 (dd, J=7.9, 2.2Hz, 1H), 7.44-7.37 (m, 2H), 7.36 (dtt, J=8. 2,1.7,0.9Hz,1H),7.20-7.14(m,1H),5.09(t,J=1.0Hz,2H),4.35(q,J=6.4Hz,2H),2.28(d,J=1.1Hz,3H),2.23(s,3H),1.38(d,J=12.8Hz,3H).

[0224] Embodiment 22:

[0225] This example provides the synthesis of compound Z22

[0226] (1) The synthetic route of compound Z22 is as follows Figure 2 shown.

[0227] Wherein, the reaction conditions are: (a) NaNO2, HCl, AcONa, pyridine, 0°C; (b) AcONa, AcOH, 110°C; (c) K2CO3, acetonitrile.

[0228] (1) Synthesis of compound Z22

[0229] a) Synthesis of compound Z22-B:

[0230] The synthesis of compound Z22-B is the same as that of Z1-C, except that 3,4-dimethylaniline (Z1-A) is replaced by p-methylaniline

[0231] b) Synthesis of compound Z22-C:

[0232] The synthesis of compound Z22-C is the same as compound Z1-D, except that Z1-C is replaced by compound Z22-B

[0233] c) Synthesis of compound Z22:

[0234] The synthesis of compound Z22 is the same as compound Z1, except that Z1-D is replaced by compound Z22-C. 1 HNMR (300MHz, CDCl3) δ7.63-7.21(m,9H),5.15(s,2H),2.41(s,3H).

[0235] Embodiment 23:

[0236] This example provides the synthesis of compound Z23

[0237] (1) The synthetic route of compound Z23 is as follows Figure 2 shown.

[0238] Wherein, the reaction conditions are: (a) NaNO2, HCl, AcONa, pyridine, 0°C; (b) AcONa, AcOH, 110°C; (c) K2CO3, acetonitrile; (d) HCl, AcOH, 110°C; (e) oxalyl chloride, DMF, DCM, N2; (f) Et3N, DCM, 0°C.

[0239] a) Synthesis of compound Z23-B:

[0240] The synthesis of compound Z23-B is the same as that of Z1-C, except that 3,4-dimethylaniline (Z1-A) is replaced by m-methylaniline

[0241] b) Synthesis of compound Z23-C:

[0242] The synthesis of compound Z23-C is the same as compound Z1-D, except that Z1-C is replaced by compound Z23-B.

[0243] c) Synthesis of compound Z23:

[0244] The synthesis of compound Z23 is the same as compound Z1, except that Z1-D is replaced by compound Z23-C. 1 HNMR (300MHz, CDCl3) δ7.50(qd,J=5.5,3.5,2.9Hz,2H),7.40-7.28(m,4H),7.28-7.17(m,3H),5.13(q,J=3.9,2.9Hz,2H),2.39(t,J=3.8Hz,3H).

[0245] Embodiment 24:

[0246] The present invention provides a synthesis of compound Z24

[0247] (1) The synthetic route of compound Z24 is as follows Figure 2 shown.

[0248] Wherein, the reaction conditions are: (a) NaNO2, HCl, AcONa, pyridine, 0°C; (b) AcONa, AcOH, 110°C; (c) K2CO3, acetonitrile.

[0249] (2) Synthesis of Z24

[0250] a) Synthesis of compound Z24-B:

[0251] The synthesis of compound Z24-B was the same as that of Z1-C, except that 3,4-dimethylaniline (Z1-A) was replaced by p-methoxyaniline;

[0252] b) Synthesis of compound Z24-C:

[0253] The synthesis of compound Z24-C is the same as compound Z1-D, except that Z1-C is replaced by compound Z24-B.

[0254] c) Synthesis of compound Z24:

[0255] The synthesis of compound Z24 is the same as compound Z1, except that Z1-D is replaced by compound Z24-C. 1 HNMR (400MHz, CDCl3) δ7.55-7.52(m,2H),7.37(d,J=2.2Hz,1H),7.35-7.33(m,4H),6.99-6.96(m,2H),5.15(s,2H),3.85(s,3H).

[0256] Test Example 1: Determination of the inhibitory activity of the test compound on breast cancer MDA-MB-231 cells

[0257] The MDA-MB-231 cell line of the present invention is derived from the Kunming Institute of Zoology, Chinese Academy of Sciences. The present invention uses the MDA-MB-231 breast cancer cell line for anti-tumor activity detection, and the drug concentration gradient is set to 0, 0.1 μM, 0.2 μM, 0.4, μM, 0.8 μM, 1 μM, with a concentration of 3×10 3 The cells were plated in 4 wells and the cell activity was detected by CCK-8 method after drug treatment for 72 hours, and the half inhibitory concentration was determined. That is, after treatment, 10 μM CCK-8 reagent was added to each well and incubated for 2 hours. The absorbance was read at a wavelength of 450 nm. The results are shown in Table 1.

[0258] Test Example 2: Determination of the binding activity of compounds to eEF2K

[0259] The present invention uses the SPR method (surface plasmon resonance method) to detect the binding ability of Z1 eEF2K. The SPR experiment was performed using Amersham Life Sciences 110397-04. A 1mM / L compound was prepared in DMSO and fixed on the photocrosslinker SensorCHIPTM. The eEF2K protein was diluted with PBST to concentrations of 200nM, 400nM, 1600nM, and 3200nM, respectively, and PBST was used as the running buffer. The eEF2K protein was injected at a flow rate of 0.5μL / s for 600s. The experiment was performed from low concentration to high concentration; the regeneration solution glycine hydrochloride (pH=2.0) was used for regeneration at a flow rate of 2μL / s. The detection time for the dissociation process was 360s. The laboratory temperature was 4°C. The raw data collected on the SPR biosensor was further processed to eliminate any artifacts, such as nonspecific binding and differences in buffer composition. The results are shown in. Figure 1 .

[0260] As shown in Table 1, 3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile compounds have good inhibitory activity against triple-negative breast cancer MDA-MB-231 cells, while compound Z4 obtained by derivatizing its cyano group to formamide completely lost its activity, and compounds Z2, Z8 and Z10 obtained by derivatizing the benzene rings on both sides to methyl or ethyl also lost their activity, indicating the importance of 3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile structure in inhibiting the activity of triple-negative breast cancer MDA-MB-231 cells.

[0261] Table 1: Inhibitory effect of compounds on breast cancer MDA-MB-231 cells at a concentration of 20 μM

[0262]

[0263]

[0264] *** represents a strong inhibition rate, that is, the inhibition rate is above 80%; ** represents a moderate inhibition rate, that is, the inhibition rate is 60-80%; ** represents a low inhibition rate, that is, the inhibition rate is 30-60%; NA represents inactivity, that is, the inhibition rate is less than 30%.

[0265] As shown in Table 2, the IC values ​​of representative compounds against triple-negative breast cancer cells MDA-MB-231 and normal breast cancer cells MCF-10A were tested. 50 Activity. The literature shows that the IC of paclitaxel for MDA-MB-231 50 =1μM (Cong HJ et al. JNat Prod. 2013), IC for MCF-10A 50=5.64 nM (Journal of Cellular Physiology (2019), 234, (4), 4277-4290). Compared with paclitaxel, the compounds protected by the present invention have comparable inhibitory activity against MDA-MB-231 cells, but weaker activity against MCF-10A cells (IC 50 >10 μM), that is, 3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile compounds have stronger antitumor activity and lower toxicity.

[0266] Table 2: Inhibitory activity of representative compounds against breast cancer MDA-MB-231 cells and normal breast cells MCF-10A cells

[0267]

[0268] like Figure 1 As shown, the representative compound Z1 exhibits a strong binding ability to eEF2K, that is, the compound selectively targets the eEF2K protein.

[0269] In summary, 3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile compounds show strong anti-malignant tumor cell activity by targeting eEF2K protein while having little effect on normal cell activity, showing strong anti-tumor potential and high safety, and therefore have great application prospects.

[0270] Obviously, the above embodiments are merely examples for clear explanation and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the protection scope of the invention.

Claims

1. A nitrile compound, characterized in that The structural formula is shown in Formula A: in, are independently selected from substituted or unsubstituted aryl or heteroaryl.

2. The nitrile compound according to claim 1, characterized in that The aryl or heteroaryl group is a substituted or unsubstituted benzene ring, naphthalene ring, biphenyl ring or an aromatic heterocycle composed of one or more N, O, and S; the substituent group in the substituted or unsubstituted aryl or heteroaryl group is selected from one or more of hydrogen, alkyl, aralkyl, heteroaryl, alkoxy, halogen, cyano, acyloxy, carbamoyl, acyl and sulfonyl.

3. The nitrile compound according to claim 2, characterized in that The aryl or heteroaryl group is a substituted or unsubstituted pyrrole ring, pyrazole ring, thiazole ring, oxazole ring, or pyridine ring.

4. The nitrile compound according to claim 1, characterized in that The nitrile compounds are 1-(4-benzyl-2-(3,4-dimethylphenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-cyano, 2-(3,4-dimethylphenyl)-4-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 2-(3,4-dimethylphenyl)-4-(3-fluorobenzyl)-3,5-dioxo-2,3, 4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 2-(3,4-dimethylphenyl)-4-(4-methylbenzyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 2-(3,4-dimethylphenyl)-4-(2-methylbenzyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 3,5-dioxo-4-(3-trifluoromethyl)benzyl)-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 2-(3,4-dimethylphenyl)-3,5-dioxo-4-propyl-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 4-ethyl-3,5-dioxo-2-phenyl-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 4-methyl-3,5 -dioxo-2-phenyl-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 4-benzyl-3,5-dioxo-2-pyridine-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 4-benzyl-2-naphthyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 2-(3,4-dimethylphenyl)-3,5-dioxo-4-(pyridine-2- 2-(1,1'-biphenyl)-4-yl)-4-benzyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 4-benzyl-2-(4-methylsulfonyl)phenyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 4-benzyl-2-(4-fluorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 2-(3,4-dimethylphenyl)-4-naphthalen-2-ylmethyl-3,5-dioxo-2,3,4 ,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 2-(3,4-dimethylphenyl)-4-(3-methylsulfonyl)benzyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 4-benzyl-3,5-dioxo-2-p-tolyl-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, 4-benzyl-3,5-dioxo-2-m-tolyl-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile or 4-benzyl-2-(4-methoxyphenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile.

5. The nitrile compound according to claim 1, characterized in that The pharmaceutically acceptable salt is selected from at least one of inorganic acid salts, organic acid salts, alkyl sulfonates and aryl sulfonates.

6. A method for preparing a nitrile compound as claimed in any one of claims 1 to 5, characterized in that: The following steps are involved: (1) reacting the compound represented by formula A1 with the compound represented by formula A2 by diazotization coupling reaction to obtain the compound represented by formula A3; (2) The compound represented by formula A3 is cyclized under acidic conditions to obtain the compound represented by formula A4, and the compound represented by formula A4 is reacted with a halogenated hydrocarbon under alkaline conditions. Substitution reaction occurs to obtain the compound represented by formula A, i.e., the nitrile compound, wherein the structural formula of the compound represented by formula A1-A4 and formula A is as follows: are independently selected from substituted or unsubstituted aryl or heteroaryl.

7. The preparation method according to claim 6, characterized in that: In step (1), the molar ratio of the compound represented by formula A1 to the compound represented by formula A2 is 1:1-1:

2.

8. The preparation method according to claim 6, characterized in that: In step (2), the pH value of the acidic condition is 1-4; the pH value of the alkaline condition is 8-10.

9. Use of the nitrile compound according to any one of claims 1 to 5 and its isomers or pharmaceutically acceptable salts or hydrates in the preparation of tumor drugs.

10. The use according to claim 9, characterized in that: The tumors are triple-negative breast cancer, lung cancer, colon cancer, breast cancer, and esophageal cancer 。

Citation Information

Patent Citations

  • Novel triazinedione derivatives as GABAB receptor modulators

    CN101679354A

  • Substituted uracils as chymase inhibitors

    CN105873919A

  • Quinoline compound composing 1,2,4-triazine-dione and use thereof

    US20130252958A1